Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Therapeutics


[Search within category]

Selective Voltage Gated KV1.3 Potassium Channel Inhibitors

Researchers at the University of California, Davis, have discovered a composition of 5-phenoxyalkoxypsoralens that inhibits potassium channels to treat autoimmune diseases and disorders that involve abnormal homeostasis, body weight and peripheral insulin sensitivity.

Antisense Oligonucleotide Therapy for B Cell Mediated Cancers

Researchers at the University of California, Davis have developed a targeted therapy using an antisense oligonucleotide (ASO) to treat precursor B cell (pre-B) acute lymphoblastic leukemia (ALL).

The Use Of Parathyroid Gland Cells And Their Secreted Factors To Promote Islet Beta Cell Engraftments

This invention identifies a novel method to increases survival of transplanted islets in extra-hepatic sites (subcutaneous and intramuscular) through co-transplantation of pancreatic islet beta cells together with parathyroid glands (PTGs). This treatment can successfully be used for patients with type I diabetes.

Identification Of OLMAINC as a Biomarker for NAFLD, NASH, Metabolic Syndrome, Hepatic Fibrosis

UCLA researchers in the Departments of Medicine and Human Genetics have identified a sequence of long, non-coding RNA that plays a role in the regulation of intracellular lipogenesis and holds potential for diagnosing and treating metabolic diseases, including NAFLD and NASH.

Inhibition of Pyruvate Oxidation to Promote Hair Growth

UCLA researchers in the departments of Molecular, Cell & Developmental Biology and Biological Chemistry have elucidated a novel mechanism by which pyruvate oxidation can be inhibited in order to promote hair growth.

Combination Hormone Therapy for Multiple Sclerosis

This invention identifies FDA-approved selective estrogen receptor modulators (SERMs), that when used alone or in combination with estrogen promote remyelination and thus can potentially be used as therapeutics for multiple sclerosis (MS).

Methods for Enhancing Cell Populations for Articular Cartilage Repair

Cartilage lesion treatments require expanding cells from healthy donor cartilage which have limited availability and restricted potential to produce cartilage. This invention overcomes these challenges, presenting chemical and physical methods for enhancing cell populations capable of producing neocartilage. According to a 2015 global market report, tissue engineering technologies are expected to reach over 94B USD by 2022.

Methods for Producing Neocartilage with Functional Potential

Cell expansion for cartilage tissue production usually leads to loss of the potential to produce cartilage, which impedes uses for cartilage repair. This invention features methods and systems for producing highly expanded primary cells to construct functional neocartilage and other neotissue. According to a 2015 global market report, tissue engineering technologies are expected to reach over 94B USD by 2022.

Methods for Treating and Alleviating Neuropathic Pain Using ApoA-I Binding Protein (AIBP)

Neuropathic pain is a type of persistent pain usually occurring longer than 3 months, associated with peripheral nerve problems, but also can arise from chronic inflammatory diseases like arthritis, chemotherapeutic-induced peripheral neuropathy in the treatment of cancer or a neurodegenerative disease or condition. The chronic pain has an extraordinary negative impact on quality of life. While opiates, NSAIDs, and anticonvulsants can relieve pain for short intervals, they are less effective for chronic therapy, particularly when components of the pain state involve persistent inflammation and/or injury to the peripheral nerve. Aside from efficacy, many of the potent agents are beset with limiting side effects and issues related to dependence and addiction. This relative lack of long-term efficacy of even approved agents is evident from clinical trial results, which often indicate that most subjects complete even successful trials with pain that is sufficiently severe as to permit reentry into the same trial. What is needed is a new treatment modality.

Use of Cell-Penetrating Peptides and/or Antibody Drug Conjugates for Tumor Radiosensitization

Tumor resistance to radiotherapy can be an obstacle to patient therapy. On way to overcome radioresistance is via the use of drugs to sensitize cells to ionizing radiation (IR). Although many radiosensitizers have been developed, their clinical benefit is hampered by a failure to improve the therapeutic ratio due to a lack of tumor specific delivery over normal tissue. To overcome this obstacle, activatable cell penetrating peptides (ACPPs) target various cargoes to sites of protease activity in vivo. ACPPs consist of a polycationic cell penetrating peptide attached to a cargo and a polyanionic inhibitory domain with a protease cleavable linker. Probe activation and cargo uptake depends on localized proteolysis of the linker sequence that connects the polyanionic and polycationic domains, which converts the probe to an adherent form. This method provides detection of spatially localized enzymatic activity in living tissues via accumulation of cleaved probe. Recently, the use of anti-tumor drugs conjugated to antibodies has been introduced as a way to increase tumor kill and improve patient outcomes.

Preconditioned Human Mesenchymal Stem Cells (hMSCs) for Musculoskeletal Tissue Repair

Researchers at the University of California, Davis have developed a preconditioning treatment and delivery method for human mesenchymal stem cell (hMSC) for enhanced bone healing.

Genes, Proteins and Small Molecule Networks Responsible for Neuronal Regeneration

Through integrative analyses of the regeneration-associated gene expression profiling after peripheral nervous system (PNS) injury, combined with multi-level bioinformatics and experimental validation of network predictions, UCLA researchers in the Department of Neurology have identified a small molecule drug that significantly accelerates and improves dorsal root ganglia (DRG) neurite outgrowth in vitro and optic nerve outgrowth in vivo.

Novel Use of Chitinases for Treatment of Lung Inflammatory and Fibrotic Diseases

A novel approach for the treatment of lung inflammatory and fibrotic diseases by increased or repaired chitinase function in lung tissues

Blocking Fragment Of CDCP1

Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. TNBC is difficult to treat since most hormone therapies target one of these receptors. Researchers at UCI have developed a therapeutic that bypasses these receptors, and instead targets fatty acid oxidation, a process linked to TNBC.

A New Preventive And Therapeutic Strategy For Liver Cancer

While the overall cancer incidences and mortality are decreasing, primary liver cancer, in particular hepatocellular carcinoma (HCC), is increasing rapidly  and has become the second leading cause of cancer-related death worldwide attributing to the rise of metabolic disorders, including alcoholic and non-alcoholic fatty liver diseases, and viral hepatitis. The significance for development of an effective prevention strategy cannot be over-emphasized, given the extremely poor prognosis of liver cancer patients at the advanced stages and the rapidly expanding population with chronic liver diseases and at high risk for subsequent liver tumorigenesis. Unfortunately, this rapid increase of the malignant disease is unmet by more efficient therapeutics in the clinic.

Soluble Epoxide Hydrolase-Conditioned Stem Cells for Cardiac Cell-Based Therapy

Researchers at the University of California, Davis, have adapted novel soluble epoxide hydrolase (sEHI) inhibitors as adjuvant treatment in cardiac cell-based therapy to improve the survival and engraftment of stem cells by pre-conditioning with the sEHI in vitro.


This invention is a novel technology developed to treat a patient’s neurological and/or psychiatric conditions. It consists of a system of implantable devices and computational algorithms that not only has autonomous control in sensing and stimulation of electrical signals in the patient’s brain, but also enables interactions with the external environment, thereby enhancing training and learning.

A Potent and Selective FXIa Inhibitor as a Next-generation Antithrombotic Drug

UCSF partnered with Pfizer’s Centers for Therapeutic Innovation (CTI) to identify an IND-ready antibody directed towards the treatment of thrombotic disease. The asset is a fully human antibody targeting the coagulation cascade serine protease FXIa for currently underserved thrombotic disease indications. A potent reversal agent has also been developed.

Targeted Inhibition of Human Multiple Myeloma

UCLA researchers in the Department of Medicine have discovered a novel mechanism involving Eph receptor/ephrin ligand interaction, that regulates human multiple myeloma growth and repopulation in vivo.

Inhibitors Of Zika Virus

UCLA researchers in the Department of Psychiatry and Biobehavioral Sciences, Department of Radiation Oncology and Department of Pathology have identified sulfonamide-based small molecules that show anti-Zika activity at low nanomolar range.

Pegylated Pleiotrophin (PEG-PTN) Promotes Hematopoietic Stem Cell Expansion and Hematopoietic Regeneration

UCLA researchers in the Department of Medicine have developed a novel pegylated recombinant PTN molecule which is capable of unique efficacy as a therapeutic molecule to promote hematopoietic reconstitution in patients.

Automated Beam Orientation and Scanning Spot Spacing Optimization for Robust Heavy Ion Radiotherapy Therapy

UCLA researchers in the Department of Radiation Oncology have developed a new method to automate and optimize heavy ion beam radiotherapeutic techniques for the treatment of cancer.

High-Throughput Microfluidic Gene-Editing via Cell Deformability within Microchannels

UCLA researchers in the Departments of Pediatrics and Chemistry & Biochemistry have developed a microfluidic device for delivery of biomolecules into living cells using mechanical deformation, without the fouling issues in current systems.

Diagnosis and Treatment of Arteriovenous Malformations

UCLA researchers in the Departments of Molecular, Cell, and Development Biology & Surgery have identified Angiopoietin 2 (Ang-2) as a marker and potentially a strong contributing factor to the clinical presentation of pulmonary arteriovenous malformations.

Novel Inhibitor of HIV Replication

UCLA researchers in the David Geffen School of Medicine have discovered a new small molecule inhibitor for HIV-1 replication.

  • Go to Page: